Skip to contentP
Pulse Biosciences, Inc.
P
PLSEPulse Biosciences, Inc. Q2 2024 · 10-Q
Revenue$0.00$0.00— vs Q2 2023 Net Income-$11.38M-$11.38MN/M vs Q2 2023 EPS, diluted—
Operating Income-$11,726,000N/M Operating Cash Flowderived-$8,395,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pulse Biosciences, Inc. · CIK 1625101 · Engraved from SEC EDGAR
Free Cash Flowderived-$8,424,000N/M ended Jun 30, 2024 · filed Aug 19, 2024 · 50 d after period end